Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to tackle tough lung cancer

NCT ID NCT05361395

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called tarlatamab, which helps the immune system find and attack cancer cells, when given together with standard chemotherapy and immunotherapy. The study includes about 184 people with extensive-stage small cell lung cancer who have not had prior treatment for this stage. The main goal is to check safety and side effects, while also looking at whether the combination helps shrink tumors or delay cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tarlatamab (a drug that helps the immune system attack cancer cells) combined with chemotherapy (carboplatin, etoposide) and an immunotherapy (atezolizumab or durvalumab)
What this could lead to
If this combination proves safe and effective, it could offer a new first-line treatment option for people with extensive-stage small cell lung cancer, potentially improving how long they live or delaying cancer growth.
What could go wrong
This is an early phase 1b trial focused on safety, so it is too soon to know if the combination works better than current treatments. Side effects from combining multiple drugs could be significant, and the results may not lead to a standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings lung neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • AZ Delta Campus Rumbeke

    Roeselare, 8800, Belgium

  • Algemeen Ziekenhuis Maria Middelares

    Ghent, 9000, Belgium

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Avera Cancer Institute

    Sioux Falls, South Dakota, 57105, United States

  • Azienda Ospedaliera Universitaria Renato Dulbecco

    Catanzaro, 88100, Italy

  • CHU de Quebec Hopital de l Enfant Jesus

    Québec, Quebec, G1R 2J6, Canada

  • Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec

    Saint-Herblain, 44800, France

  • Centre Leon Berard

    Lyon, 69373, France

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Christiana Care Health Services

    Newark, Delaware, 19713, United States

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza (MB), 20900, Italy

  • Gustave Roussy

    Villejuif, 94805, France

  • Hadassah Ein-Kerem Medical Center

    Jerusalem, 9112001, Israel

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hospital Universitari Vall d Hebron

    Barcelona, Catalonia, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Inselspital Bern

    Bern, 3010, Switzerland

  • Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol

    Badalona, Catalonia, 08916, Spain

  • Istituto Nazionale Tumori Regina Elena

    Rome, 00144, Italy

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, 3500, Belgium

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • New York University Grossman School of Medicine and New York University Langone Hospitals

    New York, New York, 10016, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center

    Haifa, 3109601, Israel

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08901, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Sheba Medical Center

    Ramat Gan, 5265601, Israel

  • Swedish Cancer Institute Medical Oncology

    Seattle, Washington, 98104, United States

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Koto-ku, Tokyo, 135-8550, Japan

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

  • Universitaetsklinikum Dresden

    Dresden, 01307, Germany

  • Universitaetsklinikum Essen

    Essen, 45147, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitaetsspital Basel

    Basel, 4031, Switzerland

  • Universitair Medisch Centrum Groningen

    Groningen, 9713 GZ, Netherlands

  • Universitair Ziekenhuis Antwerpen

    Edegem, 2650, Belgium

  • University of Southern California, Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • West Virginia University Health Sciences Center

    Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.